| Objective To evaluate the clinical efficacy and safety of Suyin Jiedu Granules combined with finerenone in the treatment of diabetic kidney disease (DKD) with dampness?heat and blood stasis syndrome. Methods A total of 96 patients with stage III?IV DKD (dampness?heat and blood stasis syndrome) admitted from June 2022 to December 2023 were randomly divided into two groups, with 48 cases in each group. Both groups received conventional treatment including hypoglycemic, antihypertensive and lipid?regulating therapies. On this basis, the control group was treated with finerenone, while the observation group was treated with Suyin Jiedu Granules combined with finerenone. The treatment course was 6 months. The changes in urinary albumin?to?creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), serum creatinine (Scr), blood urea nitrogen (BUN), inflammatory factors (TNF?α, IL?6), clinical comprehensive efficacy and adverse events were compared between the two groups before and after treatment. Results After treatment, UACR, Scr, BUN and inflammatory factor levels in both groups decreased significantly (P<0.05). Compared with the control group, the observation group showed a more significant reduction in UACR (P<0.05), lower levels of TNF?α and IL?6 (P<0.05), and a significant increase in eGFR compared with that before treatment (P<0.05). The clinical total effective rate in the observation group (89.58%) was significantly higher than that in the control group (72.92%) (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05), and no severe adverse events occurred. Conclusion On the basis of finerenone and conventional treatment, the addition of Suyin Jiedu Granules can more effectively reduce urinary protein levels, alleviate systemic inflammation, and improve renal function in patients with DKD, without increasing the risk of adverse reactions. It is a safe and effective therapeutic option for DKD with dampness?heat and blood stasis syndrome. |